

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

東瑞製藥(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2348)

CLARIFICATION ANNOUNCEMENT RELATING TO GRANT OF SHARE OPTIONS

Reference is made to the announcement of the Company dated 18 June 2019 (the “**Announcement**”) in respect of the proposed grant (the “**Proposed Grant**”) of 64,000,000 share options (the “**Options**”) of the Company to Mr. Chen Shaojun (“**Mr. Chen**”), the executive Director and the chief executive officer of the Company. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

In order to comply with the Listing Rules, the Board has cancelled the Proposed Grant on 1 August 2019 with the agreement of Mr. Chen at nil consideration. The Company may consider granting share options to Mr. Chen in the future.

By Order of the Board
Dawnrays Pharmaceutical (Holdings) Limited
Li Kei Ling
Chairman

Hong Kong, 1 August 2019

As at the date of this announcement, the Board of the Company comprises three executive directors, namely Ms. Li Kei Ling, Mr. Hung Yung Lai and Mr. Chen Shaojun; one non-executive director, namely Mr. Leung Hong Man; three independent non-executive directors, namely Mr. Lo Tung Sing Tony, Mr. Ede, Ronald Hao Xi and Ms. Lam Ming Yee Joan.

**for identification purpose only*